ABBV
AbbVie Inc.
NYSE: ABBV · North Chicago, IL · Healthcare
$285.64+0.45 (+0.16%)Closed
Market Cap$504.76B
Cash$6.57Bmost recent
Runwayprofitable
P/E (TTM)121.0EPS $2.36
52-Wk Range$194.79 – $289.08
Avg Volume6.2M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$285.64+60.5%
Pipeline
Drug candidates sponsored by AbbVie · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Adalimumab | Rheumatoid Arthritis | Completed | 2013-01past | 1 | |
| Phase 4 | Pancrelipase | Cystic Fibrosis | Completed | 2022-07-11past | 1 | |
| Phase 4 | Atogepant | Episodic Migraine | Completed | 2023-04-04past | 1 | |
| Phase 4 | OnabotulinumtoxinA | Jawline and Neck Appearance | Recruiting | 2027-06 | 1 | |
| Phase 3 | ABT-874 | Moderate to Severe Plaque Psoriasis | Completed | 2009-04past | 1 | |
| Phase 3 | Levodopa-carbidopa intestinal gel | Dyskinesias+2 more | Completed | 2012-10past | 1 | |
| Phase 3 | paricalcitol | End-Stage Renal Disease+1 more | Completed | 2015-04past | 1 | |
| Phase 3 | ombitasvir/paritaprevir/ritonavir | Chronic Hepatitis C+2 more | Completed | 2016-06-13past | 1 | |
| Phase 3 | ombitasvir/paritaprevir/ritonavir and dasabuvir | Hepatitis C Virus (HCV) | Completed | 2016-10past | 1 | |
| Phase 3 | Paclitaxel | Non-squamous Non-small Cell Lung Cancer | Completed | 2019-11-14past | 1 | |
| Phase 3 | placebo for risankizumab IV | Crohn's Disease | Completed | 2020-11-30past | 1 | |
| Phase 3 | Placebo | Ulcerative Colitis (UC) | Completed | 2021-01-14past | 1 | |
| Phase 3 | Placebo for Upadacitinib | Atopic Dermatitis | Completed | 2021-03-11past | 1 | |
| Phase 3 | Cariprazine | Major Depressive Disorder+3 more | Completed | 2022-09-05past | 2 | |
| Phase 3 | Mirvetuximab Soravtansine | Epithelial Ovarian Cancer+2 more | Completed | 2023-03-06past | 1 | |
| Phase 3 | Unnamed | Perioral Lines | Completed | 2024-09-03past | 1 | |
| Phase 3 | Tavapadon | Parkinson Disease | Completed | 2024-10-01past | 1 | |
| Phase 3 | Placebo for Linaclotide | Functional Constipation (FC)+1 more | Completed | 2025-09-02past | 1 | |
| Phase 3 | Cariprazine Flexible Dose | Schizophrenia+2 more | Completed | 2025-10-06past | 1 | |
| Phase 2 | Livmoniplimab | Hepatocellular Carcinoma+1 more | Active, not recruiting | 2027-01 | 2 | |
| Phase 3 | Risankizumab | Psoriasis+4 more | Recruiting | 2028-09 | 4 | |
| Phase 3 | Upadacitinib | Rheumatoid Arthritis+2 more | Recruiting | 2030-04 | 3 | |
| Phase 2 | Telisotuzumab Adizutecan | Non-Small Cell Lung Cancer+1 more | Recruiting | 2030-09 | 1 | |
| Phase 3 | Etentamig | Amyloid Light Chain (AL) Amyloidosis+1 more | Recruiting | 2034-12 | 3 | |
| Phase 2 | ABT-288 | Alzheimer's Disease | Completed | 2011-02past | 1 | |
| Phase 2 | ABT-126 | Cognitive Deficits in Schizophrenia | Completed | 2011-08past | 1 | |
| Phase 2 | hydrocodone/acetaminophen extended release | Chronic Low Back Pain | Completed | 2011-10past | 1 | |
| Phase 2 | ABT-869 | Advanced Renal Cell Carcinoma+1 more | Completed | 2012-04past | 2 | |
| Phase 2 | ABT-652 6 mg | Diabetic Neuropathic Pain | Terminated | 2012-05past | 1 | |
| Phase 2 | Atrasentan low dose group | Chronic Kidney Disease+1 more | Completed | 2012-07past | 1 | |
| Phase 2 | ABT-450 | Hepatitis C Virus | Completed | 2013-05past | 1 | |
| Phase 2 | temozolomide | Melanoma+2 more | Completed | 2016-01past | 1 | |
| Phase 2 | ABT-122 | Rheumatoid Arthritis | Completed | 2016-05past | 1 | |
| Phase 2 | elotuzumab | Hematologic Cancer | Completed | 2016-10past | 1 | |
| Phase 2 | ABT-450/r | Chronic Hepatitis C | Completed | 2017-05-03past | 1 | |
| Phase 1 | Rovalpituzumab tesirine | Malignant Melanoma+7 more | Terminated | 2019-08-27past | 1 | |
| Phase 2 | Tilavonemab | Alzheimer's Disease | Terminated | 2021-09-30past | 1 | |
| Phase 2 | Ibrutinib | CoronaVirus Induced Disease-2019 (COVID-19)+1 more | Completed | 2022-02-09past | 2 | |
| Phase 2 | AGN-151607 | Post-Operative Atrial Fibrillation | Completed | 2022-03-24past | 1 | |
| Phase 2 | Elezanumab | Spinal Cord Injury (SCI) | Completed | 2026-01-26past | 1 | |
| Phase 2 | Eluxadoline | Irritable Bowel Syndrome | Completed | 2026-08-17past | 1 | |
| Phase 2 | Venetoclax | Chronic Lymphocytic Leukemia (CLL)+1 more | Recruiting | 2026-11 | 2 | |
| Phase 2 | Lutikizumab | Hidradenitis Suppurativa | Active, not recruiting | 2027-12 | 1 | |
| Phase 2 | ABBV-142 | Idiopathic Pulmonary Fibrosis | Recruiting | 2029-09 | 1 | |
| Phase 1 | ABT-333 | Relative Bioavailability | Completed | 2013-12past | 1 | |
| Phase 1 | ABT-957 | Alzheimer's Disease | Terminated | 2016-03past | 1 | |
| Phase 1 | veliparib (ABT-888) | Advanced Solid Tumors | Completed | 2016-08past | 1 | |
| Phase 1 | Veliparib | Gastric Cancer+5 more | Completed | 2016-09past | 2 | |
| Phase 1 | SC-007 | Colorectal Cancer (CRC)+1 more | Terminated | 2018-03-20past | 1 | |
| Phase 1 | ABBV-0805 | Parkinson's Disease | Withdrawn | 2020-06-16past | 1 | |
| Phase 1 | ABBV-181 | Head and Neck Cancer | Terminated | 2020-09-23past | 1 | |
| Phase 1 | ABBV-467 | Multiple Myeloma (MM)+1 more | Terminated | 2021-04-16past | 1 | |
| Phase 1 | Lutikizumab Dose A | Healthy Volunteers | Completed | 2024-02-26past | 1 | |
| Phase 1 | ABBV-552 | Healthy Volunteer | Completed | 2024-04-19past | 1 | |
| Phase 1 | ABBV-903 | Healthy Volunteers | Withdrawn | 2025-01-31past | 1 | |
| Phase 1 | ABBV-787 | Acute Myeloid Leukemia | Terminated | 2025-02-25past | 1 | |
| Phase 1 | Emraclidine | Healthy Participants+1 more | Completed | 2025-04-14past | 1 | |
| Phase 1 | Eftozanermin alfa | Multiple Myeloma | Terminated | 2025-05-05past | 1 | |
| Phase 1 | GUB014295 | Healthy Volunteers+1 more | Completed | 2026-01-05past | 1 | |
| Phase 1 | ABBV-1162 | Healthy Volunteers | Not yet recruiting | 2027-05 | 1 | |
| N/A | Unnamed | Human Immunodeficiency Virus Infection | Completed | 2011-12past | 1 | |
| N/A | Unnamed | Chronic Kidney Failure+1 more | Completed | 2012-01past | 1 | |
| N/A | Unnamed | Psoriasis | Completed | 2012-07past | 1 | |
| N/A | Unnamed | Moderate to Severe Psoriasis | Terminated | 2013-08past | 1 | |
| N/A | Unnamed | HIV-1 Infection | Completed | 2014-10past | 1 | |
| N/A | Unnamed | Rheumatoid Arthritis | Completed | 2017-12-28past | 1 | |
| N/A | Unnamed | Chronic Hepatitis C Virus (HCV) | Completed | 2018-04-25past | 1 | |
| N/A | Unnamed | Axial Spondyloarthritis | Terminated | 2018-09-14past | 1 | |
| N/A | Unnamed | Crohn's Disease+6 more | Completed | 2019-02-28past | 1 | |
| N/A | Unnamed | Psoriasis | Completed | 2019-08-06past | 1 | |
| N/A | Unnamed | Psoriatic Arthritis | Completed | 2019-11-19past | 1 | |
| N/A | Unnamed | Ankylosing Spondylitis | Completed | 2019-12-16past | 1 | |
| N/A | Unnamed | Parkinson Disease (PD) | Completed | 2020-02-26past | 1 | |
| N/A | Unnamed | Intestinal Behcet's Disease (BD) | Completed | 2020-03-30past | 1 | |
| N/A | Unnamed | Non-infectious Intermediate, Posterior and Panuveitis | Completed | 2020-07-16past | 1 | |
| N/A | Unnamed | Polyarticular Juvenile Arthritis | Completed | 2020-09-14past | 1 | |
| N/A | Unnamed | Endometriosis+2 more | Terminated | 2020-11-19past | 1 | |
| N/A | Unnamed | Hepatitis C Virus (HCV) | Completed | 2021-06-11past | 1 | |
| N/A | Unnamed | Ankylosing Spondylitis (AS)+2 more | Completed | 2021-07-08past | 1 | |
| N/A | Unnamed | Hepatitis C | Completed | 2023-07-21past | 1 | |
| N/A | Unnamed | Migraine | Completed | 2024-08-05past | 1 | |
| N/A | Unnamed | Crohn's Disease | Recruiting | 2026-11 | 1 | |
| N/A | Unnamed | Parkinson's Disease (PD) | Active, not recruiting | 2027-01 | 1 | |
| N/A | Unnamed | Crohn's Disease | Recruiting | 2027-12 | 1 | |
| N/A | Unnamed | Ulcerative Colitis | Active, not recruiting | 2028-03 | 1 | |
| N/A | Unnamed | Ulcerative Colitis | Recruiting | 2028-07 | 1 | |
| N/A | Unnamed | Chronic Lymphocytic Leukemia (CLL) | Recruiting | 2030-12 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for ABBV. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.